- Causaly, a London startup that has built an AI platform to help researchers accelerate the development and testing of drugs, has raised $60 million, a Series B that will be going toward R&D and to continue building out its team.
- CEO Kiachopoulos estimated that the use of Causaly’s platform can reduce the 10-15 years that it might typically take to take an idea from target to the end of trials, down to around “several” years.
